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ABSTRACT Cardiac myosin binding protein C (cMyBP-C) is an important regulator of cardiac contractility. Its precise effect on
myosin cross-bridges (CBs) remains unclear. Using a cMyBP-C/ mouse model, we determined how cMyBP-C modulates the
cyclic interaction of CBs with actin. From papillary muscle mechanics, CB characteristics were provided using A. F. Huxley’s
equations. The probability of myosin being weakly bound to actin was higher in cMyBP-C/ than in cMyBP-C1/1. However, the
number of CBs in strongly bound, high-force generated state and the force generated per CB were lower in cMyBP-C/. Overall
CB cycling and the velocity of CB tilting were accelerated in cMyBP-C/. Taking advantage of the presence of cMyBP-C in
cMyBP-C1/1 myosin solution but not in cMyBP-C/, we also analyzed the effects of cMyBP-C on the myosin-based sliding
velocity of actin ﬁlaments. At baseline, sliding velocity and the relative isometric CB force, as determined by the amount ofa-actinin
required to arrest thin ﬁlament motility, were lower in cMyBP-C/ than in cMyBP-C1/1. cAMP-dependent protein kinase-
mediated cMyBP-C phosphorylation further increased the force produced by CBs. We conclude that cMyBP-C prevents
inefﬁcient, weak binding of themyosin CB to actin and has a critical effect on the power-stroke step of themyosin molecular motor.
INTRODUCTION
Cardiac contraction involves the cyclic interaction of the
myosin cross-bridges (CBs) with the actin filaments. This is a
highly regulated process that couples ATP hydrolysis to
motility and force generation (1,2). Whereas low Ca21 levels
prevent actin-myosin interactions in diastole, the rise in in-
tracellular Ca21 during systole initiates a series of confor-
mational changes that cause the myosin CBs to bind to
activated thin filaments. Binding occurs in one of two ways,
either weakly or strongly (3,4). The initial weak binding to
actin isomerizes to a strongly bound, force-generating step
often referred to as the power-stroke, which moves the actin
filament past the myosin filaments and generates force. This
is associated with rotation of the light-chain binding region
and the release of the ATP hydrolysis products. The associ-
ation of a new ATP molecule weakens the binding again, and
the attached CB rapidly dissociates from actin. The nucleo-
tide is then hydrolyzed, the conformational change reverses,
and the myosin CB can reattach to actin (4,5).
Cardiac myosin-binding protein C (cMyBP-C), for which
mutations are one of the major causes of familial hypertro-
phic cardiomyopathy (FHC) (for reviews see (6,7)), is a large
thick filament-associated protein that consists of 11 modules
labeled C0 to C10 from the N- to the C-terminus. cMyBP-C
binds to the heavy meromyosin through its C10 domain
whereas the MyBP-C motif, a phosphorylable motif linking
the C1 and C2 domains, binds to the myosin subfragment S2
(8) close to the lever arm domain of myosin. Phosphorylation
of the MyBP-C motif results in a rearrangement of the my-
osin head and the structure of the thick filament (9). cMyBP-C
also binds titin via domains C8-C10 (10) and actin in the Pro-
Ala rich sequence between the C0 and C1 domains (11).
There is increasing evidence that cMyBP-C plays a critical
role in the regulation of cardiac contractility. It has been
proposed that cMyBP-C is involved in the activation process
of the cardiac sarcomere (12–15). Accordingly, previous
studies suggest that cMyBP-C modulates myofilament Ca21
sensitivity (13,16–18) probably via sarcomere length-
dependent activation (18). In addition, it is assumed that
ablation of cMyBP-C relieves a physical constraint on my-
osin, which then allows myosin to move radially from the
surface of the thick filament. This would increase the likeli-
hood of CB formation (14,19) and accelerated CB cycle ki-
netics (15,17,20). However, questions remain as to which
step cMyBP-C regulates in the actin-myosin cycle and how
potential modifications of the myosin CB cycle contribute to
the cardiac dysfunction.
This study was undertaken to determine the functional
effects of cMyBP-C on the essential states of interaction of
myosin heads with actin so as to understand how cMyBP-C
interferes with the actin-myosin CB cycle. To this end, we
used a homozygous cardiac cMyBP-C-null mice (cMyBP-
C/) based upon the targeted deletion of the transcription
initiation site and exons 1–2 of the mouse cMyBP-C gene
(21,22).
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MATERIALS AND METHODS
Mouse models
Cardiac cMyBP-C-null mice were generated previously (21) and maintained
in a breeding colony. Briefly, the mouse model was based upon the targeted
deletion of the transcription initiation site and exons 1–2 of the mouse
cMyBP-C gene (21). In this study, cMyBP-C1/1 and cMyBP-C/ (n ¼ 20
in each group) mice of either sex were studied at 16 weeks of age. Electro-
phoretic andWestern blot analyses confirmed the absence of cMyBP-C in the
null mice (21). Experiments were also performed in a cMyBP-C1/1 mouse
model of either sex fed an iodine-deficient, 0.15% 6-n-propyl-2-thiouracil
(PTU) diet before study (cMyBP-C1/11PTU, n ¼ 12). Duration of PTU
therapy was determined so as to obtain similar shift in the myosin isoform
pattern in cMyBP-C1/11PTU and cMyBP-C/ mice. All procedures
conformed to the Guide for Care and Use of Laboratory Animals and have
been approved by the local committee of our institution.
Papillary muscle preparations
Mechanical experiments were performed on LV papillary muscle as previ-
ously described (23). Briefly, after an IP injection of sodium pentobarbital,
the heart was rapidly excised and placed in a physiological solution. The LV
was opened under a dissection microscope and the anterior papillary muscle
was carefully dissected. The muscle was then placed in a circulating organ
bath containing modified Krebs-Henseleit buffer solution (24) with 5% fetal
calf serum. The solution was bubbled with 95% O2 and 5% CO2 and
maintained at 29C and pH 7.4. One end of the extremity of the papillary
muscle was held by a stationary clip and the other was maintained with
another clip attached to an isotonic electromagnetic force-transducer lever.
After an equilibration period of 30 min, muscle was supramaximally stim-
ulated using two platinum electrodes at the optimal force-frequency re-
sponse, i.e., at a frequency of six stimulations/min. Experiments were
performed at Lmax, the initial muscle length at which active isometric tension
was maximum. The CSA was calculated as previously described (25).
Papillary muscle mechanical parameters
Muscle mechanical parameters and parameters determined from A. V. Hill’s
equation were determined over the whole load continuum (24,26). During
the contraction phase, we recorded the maximum unloaded shortening ve-
locity (Vmax, in Lmax.s
1) from the zero-load contraction; the maximum
extent of shortening (dL, in % Lmax) and the time-to-peak shortening (TPS) of
the contraction loaded with preload only; the peak isometric tension, i.e.,
peak force normalized per CSA (Pmax, in mN.mm
2); and the positive peak
of isometric tension derivative of the fully isometric contraction (1dP/dt,
mN.mm2.s1). To characterize the relaxation process, we measured the
peak lengthening velocity at preload (VL, in Lmax.s
1) and the peak rate of
tension decline of the fully isometric contraction (dP/dt, in mN.s1.
mm2). The hyperbolic tension-velocity (P-V) relationship was derived from
the peak velocity of 8–10 isotonic after loaded contractions and was fitted
according to Hill’s equation (P1a) (V1b) ¼ [Pmax1a]b where a and b
are the asymptotes of the hyperbola as determined by multilinear regression
(26). The G curvature of the P-V curve is equal to Pmax/a ¼ Vmax/b (26).
CB kinetics and probabilities of CB steps
The actomyosin interaction was analyzed according to a multistate confor-
mational model based on Huxley’s original CB model (27) and consistent
with recent models of muscle contraction (4,5). Initial CB attachment occurs
with a rate constant f1 and leads to the formation of a weakly attached, low-
force state (AM-ADP-Pi). After transition to a strongly bound, high-force
state, the attached CB AM-ADP-Pi executes a power-stroke, causing a rel-
ative displacement of the actin filament. This state, triggered by the release of
Pi leads to the formation of AM-ADP. The release of ADP occurs after the
power-stroke step and leads to the formation of AM. Then, the binding of one
ATP molecule to the myosin head causes the actomyosin complex to detach
(A1M-ATP). The rate constant for cross-bridge detachment was g2. ATP
hydrolysis then occurs (M*-ADP-Pi) where M* is myosin in a refractory
state (28). This leads to a conformational change in myosin (M-ADP-Pi)
allowing a new cycle to begin.
A. F. Huxley’s equations (27) were used to calculate the total duration of
the CB cycle under isometric conditions (in milliseconds); the duration of the
power-stroke step (in milliseconds); CB velocity during the stroke (vo, in
mm.s1); the elementary force per single CB (in piconewtons); the number of
active CBs, peak efficiency (Effmax, in %); the peak value of the rate con-
stant for CB attachment during the stroke step (f1, in s
1); and the peak value
of the rate constant for CB detachment during (g1, in s
1) and after the stroke
step (g2, in s
1) (24,29). The free energy of ATP hydrolysis (e) was chosen to
be equal to 5.13 1020 J (24,29), the distance ‘ between two actin sites was
equal to 14.3 nm (27) and h, the translocation distance of the actin filament
per ATP hydrolysis produced by the swing of the myosin head was equal to
5 nm (30). In cycling myosin molecules, the probability of actomyosin states
was calculated from the ratio of their time duration and the time cycle (1).
Briefly, the probability of cycling myosin being in the detached state M-ATP
is given byPD1¼ (1/ g2)/time cycle. The probability of actomyosin being in a
weakly attached, low-force state (AM*-ADP-Pi) is given by PA1 ¼ (1/f1)/
time cycle. The probability of actomyosin being in a strongly-bound high
force state (AM-ADP state) is PA2 ¼ time stroke/time cycle (1).
In vitro motility assays
Mouse LV myosin was isolated as previously described (23,31) and used
within 48 h. To determine whether cMyBP-C affects myosin mechanical
properties, we took advantage of the fact that cMyBP-C is a classic con-
taminant of myosin preparation (32). SDS-Page electrophoresis was used to
assess the purity of myosin and the presence of cMyBP-C was detected by
Western-blot using a polyclonal antibody directed against the cMyBP-C
motif (generous gift from Wolfgang Linke, Mu¨nster, Germany). F-actin was
prepared from rabbit skeletal muscle by standard methods (33) and fluo-
rescently labeled with phalloidin FluoProbes 547 (Interchim, Montlucon,
France). Motility assays were carried out at 29C as previously described
(31,34). In brief, myosin (100mg/ml in high salt buffer containing 40 mmol/L
potassium phosphate buffer, 1 mol/L KCl, 2 mmol/L dithiothreitol, and 4 mM
MgCl2, pH 6.5) was plated onto a nitrocellulose-coated glass coverslip. Un-
bound myosin was washed out with low salt buffer (25 mmol/L KCl, 25
mmol/L imidazole, 4 mmol/L MgCl2, 1 mmol/L dithiothreitol, and 1 mmol/L
ethylene glycol-bis (b-aminoethyl ether, pH 7.4) supplemented with 0.5mg/ml
bovine serum albumin. Unlabeled F-actin filaments were used to eliminate
nonfunctional myosin molecules (35). Motility of fluorescently labeled actin
filaments (20 nmol/L) was initiated by adding 2 mmol MgATP with an
oxygen-scavenger enzyme system (20 mmol dithiothreitol, 0.02 mg/ml
catalase, 0.1 mg/ml glucose oxidase, 3 mg/ml glucose). The movement of the
actin filaments was observed under a Zeiss epifluorescence microscope
(model No. 200, 100/1.30 lens, Axiovert, Jena, Germany) equipped with an
intensified camera (model No. C 2400, Hamamatsu, Hamamatsu City, Japan)
and recorded on videotape. The mean velocities of each filament were ana-
lyzed using N. J. Carter’s freeware RETRAC program.
Effects of cAMP-dependent protein kinase (PKA)
To assess the effects of cMyBP-C phosphorylation on myosin mechanical
properties, myosin solution was preincubated for 15 min at 22C with 10
mmol of catalytic subunit of cAMP-dependent protein kinase (PKA) (Sigma
Chemical, St. Louis, MO) before use in the motility assay. Phosphorylation
under basal conditions and after PKA treatment was determined byWestern-
blot using a polyclonal antibody directed against the phosphorylated Ser82 of
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cMyBP-C forms (ALX-215-057, Axxora, San Diego, CA) (36). Im-
munodetection was revealed with the ECL system (ECL-Plus kit, Amersham
Pharmacia, Piscataway, NJ).
Relative force of myosin molecules
Relative isometric force was determined by using a-actinin as an internal
load (37,38). In brief, myosin was adhered to the nitrocellulose-coated
coverslip as described above. Alpha-actinin was then attached to the cov-
erslip surface (15–100mg/ml in low-salt buffer), followed by a bovine serum
albumin wash (0.5 mg/ml in low-salt buffer). Unregulated actin filaments (20
nmol/L) were then added to the motility surface. Motility was initiated by the
addition of 2 mmol MgATP with the oxygen-scavenger enzyme system, as
described above. As a-actinin avidly binds to actin, the motion of the thin
filament is impeded by the a-actinin adhered to the surface. The load placed
on a thin filament is a function of the relative concentrations of the force
generator (myosin) and the motion inhibitor (a-actinin). The amount of
a-actinin adhered to the motility surface was gradually increased until mo-
tility was completely arrested, thus indicating an isometric state. Relative
isometric force was then defined as the minimum amount of a-actinin needed
to completely arrest thin filament motility.
Myosin isoform composition
Myosin isoform composition was determined on purified myosin obtained
from both LV and papillary muscle and stored in 50% glycerol. Alpha- and
b-myosin isoforms were separated on 8% polyacrylamide gels containing
10% glycerol (23). SDS-PAGE was performed in a Mini-Protean II Dual
Slab Cell electrophoresis system (BioRad, Hercules, CA) for 16 h at 4C and
70 V. Gels were stained with Coomassie blue and quantification of a- and
b-myosin isoforms were quantified using Image Gauge software.
Statistical analysis
Data are expressed as mean 6 SE. After analysis of variance, differences in
selected measurements between groups were evaluated by Fisher’s test. All
comparisons were two-tailed and a p-value , 0.05 was considered statisti-
cally significant.
RESULTS
Mechanical performance of in vitro LV
papillary muscle
Contractile mechanical parameters of LV papillary muscles
are given in Table 1. Compared with cMyBP-C1/1, con-
tractile performance was severely depressed in cMyBP-C/,
as attested by a reduction in maximum extent of shortening
(dL), maximum unloaded shortening velocity (Vmax), total
tension (Pmax), and 1dP/dt (58%, 45%, 57%, and
59% respectively, each p , 0.05). Peak shortening oc-
curred significantly earlier in cMyBP-C/ than in cMyBP-
C1/1 (Table 1; p, 0.05). Interestingly, depressed contractile
performance in cMyBP-C/ mice was associated with
severe impairment of relaxation (Table 1), as attested by
slower dP/dt and maximum lengthening velocity (VL) in
cMyBP-C/ compared with cMyBP-C1/1 (67% and
67%, respectively, each p , 0.001).
Cyclical interactions of the myosin CB with actin
in papillary muscles
We used a multistate conformational model based on A. F.
Huxley’s original CB model (27) to characterize CB prop-
erties in cMyBP-C1/1 and cMyBP-C/ papillary muscles.
The number of active CBs, i.e., CBs involved in the power-
stroke during isometric contraction was almost 45% lower in
cMyBP-C/ than in cMyBP-C1/1 (p , 0.001, Fig. 1 A).
Moreover, the force produced per CB was 23% lower in
cMyBP-C/ than in cMyBP-C1/1 mice (Fig. 1 B, p ,
0.001). This was associated with a 29% reduced of CB effi-
ciency in cMyBP-C/ (Fig. 1 C). Lack of cMyBP-C also
induced step-dependent modifications of the CB kinetics.
The velocity of CB tilting during the stroke was accelerated
by 182% in cMyBP-C/ compared with cMyBP-C1/1 (Fig.
1D, p, 0.01) and the duration of the stroke was 62% shorter
in cMyBP-C/ compared with cMyBP-C1/1 (2.3 vs. 6.1
ms, respectively, p , 0.01). In addition, the overall duration
of the CB cycle was 38% shorter in cMyBP-C/ (p, 0.01,
Fig. 2 A). There was no difference in the maximum rate
constant for CB attachment (f1) between groups (320 6 60
vs. 276 6 35 ms1 in cMyBP-C/ and cMyBP-C1/1, re-
spectively). The maximum rate constant for CB detachment
(g2) was 45% lower in cMyBP-C
/ than in cMyBP-C1/1
(5276 102 vs. 9576 131 ms1 respectively, p, 0.05). The
probability of myosin being weakly bound to actin (PA1) was
60% higher in cMyBP-C/ than in cMyBP-C1/1 (Fig. 2 B,
p , 0.001). However, the probability of a strongly bound,
high-force generated state (AM-ADP1 Pi state) was reduced
by 38% lower in cMyBP-C/ compared with cMyBP-C1/1
(Fig. 2 C, p , 0.001). In addition, the probability of cycling
myosin being in the M-ATP detached state was 134% higher
in cMyBP-C/ than in cMyBP-C1/1 hearts (Fig. 2 D, p ,
0.001).
TABLE 1 Performance of LV papillary muscles during the
contraction and relaxation phases
cMyBP-C1/1 cMyBP-C/
Contraction parameters
dL, % Lmax 6.9 6 0.7 2.9 6 0.8*
Vmax, Lmax/s 2.4 6 0.3 1.3 6 0.3
y
Pmax, mN/mm
2 24.5 6 2.2 10.5 6 1.4*
1dP/dt, mN/mm2/s 125.2 6 19.8 51.4 6 11.9*
TPS, ms 120 6 4 105 6 5y
Relaxation parameters
dP/dt, mN/mm2/s 206.5 6 23.4 68.8 6 14*
VL, Lmax/s 1.2 6 0.1 0.4 vs. 0.1*
dL, maximum extent of shortening at preload; Vmax, maximum shortening
velocity at zero-load; Pmax, total isometric tension; 1dP/dt, positive peak
derivative of isometric tension; TPS, time-to-peak shortening at preload;
dP/dt, negative peak derivative of isometric tension; VL, peak lengthening
velocity at preload. Values are means 6 SE.
*p , 0.01, N ¼ 8 in each group.
yp , 0.05;
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In vitro motility of the myosin CB with actin
cMyBP-C is a known contaminant of purified myosin prep-
aration (32), and significant amount of cMyBP-C was present
in the purified myosin solutions as attested by Western-blot
analysis (Fig. 3 A). Hence, we evaluated the effects of
cMyBP-C on actomyosin interactions by analyzing in vitro
motility of actin filaments sliding over LV myosin prepara-
tion. As compared with cMyBP-C1/1, velocity driven by
myosin from cMyBP-C/ was shifted toward lower values,
mean velocities being ;18% lower in cMyBP-C/ than in
cMyBP-C1/1 (Fig. 4, A and B, p , 0.001). Force produced
by myosin was determined by loading actin filaments with
a-actinin, an actin-binding protein that acts as an internal
load on the force generator (myosin) and impedes the motion
of the thin filament (37,38). In both groups, the fraction of
mobile filaments linearly decreased by increasing the amount
of a-actinin (Fig. 4D). However, the x axis intercept of linear
regression fits of the data was 60% lower in cMyBP-C/
than in cMyBP-C1/1 (29.1 6 0.1 vs. 74.4 6 1.1 mg/ml,
respectively, p, 0.001), indicating that the lack of cMyBP-C
significantly decreased the concentration of a-actinin re-
quired to arrest actin filament sliding. This suggests that
cMyBP-C improved the force generated per active CB.
Effects of phosphorylation levels of cMyBP-C on
the myosin CB
Because phosphorylation/dephosphorylation of cMyBP-C
induces rapid and reversible changes in thick filament
structure and ordering of myosin heads that possibly modu-
late the rate of CB cycling (39,40), we next examined the
effects of PKA-mediated cMyBP-C phosphorylation on CB
mechanics. PKA treatment of cMyBP-C1/1myosin solution
induced a 59% increase in cMyBP-C phosphorylation com-
pared with basal values (12.4 6 1.6 vs. 7.8 6 1.2 AU, p ,
0.001, Fig. 3 B). Interestingly, this was associated with a 53%
FIGURE 1 Effects of cMyBP-C ablation on CB charac-
teristics. Compared with cMyBP-C1/1 (1/1), the total
number of active CBs (A), the unitary force per active CB
(B), and CB efficiency (Effmax, C) were significantly
reduced in cMyBP-C/ (/). The velocity of the CB
during the stroke (vo, D) was higher in cMyBP-C
/. PTU-
treated mice (1/11PTU) did not significantly differ from
cMyBP-C1/1. Values are means6 SE, N ¼ 8/group; *p,
0.01; §p , 0.001.
FIGURE 2 Effects of cMyBP-C ablation on kinetics and
CB cycle probabilities. Duration of the ATP-ADP-Pi-acto-
myosin CB cycle (A), probability of actomyosin being
weakly bound (B), strongly bound (C) and in the M-ATP
detached state (D). PTU-treated mice (1/11PTU) did not
differ significantly from cMyBP-C1/1. Values are means6
SE, N ¼ 8/group; *p , 0.01, §p , 0.001.
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increase in the amount of a-actinin required to arrest thin
filament motility (113.6 6 0.4 vs. 74.4 6 1.1 mg/ml, re-
spectively, p , 0.001; Fig. 4 D). Thus, phosphorylation of
cMyBP-C induced a significant increase in the force pro-
duced by CB, suggesting a specific effect on the power-stroke
step. No significant difference in the sliding velocity was
observed in PKA-treated myosin (1.98 6 0.01 mm/s, Fig.
4 C) vs. untreated myosin (1.97 6 0.01 mm/s, Fig. 4 A)
isolated from cMyBP-C1/1.
Potential effects of MHC isoforms on
actomyosin interactions
a-MHC represented the major fraction of MHC isoform in
cMyBP-C1/1 (Fig. 5). cMyBP-C/ exhibited a 124% in-
crease in the relative expression of b-MHC (p , 0.001).
There was no significant difference between LV and papil-
lary muscle as regards MHC composition in both groups
(data not shown). To determine whether the changes in
functional capacities in cMyBP-C/ were related to a MHC
shift, experiments were performed in cMyBP-C1/1 mice in
which a 25% shift toward b-MHC was induced by a short-
term, iodine-deficient, 0.15% 6-n-propyl-2-thiouracil (PTU)
diet (Fig. 5). Compared with cMyBP-C1/1, mechanical
and CB properties obtained with papillary muscles did not
differ between PTU-treated and untreated cMyBP-C1/1
mice (Figs. 1 and 2). Furthermore, no changes in the
sliding velocity or in the amount of a-actinin required to
arrest thin filament motility were observed between
cMyBP-C1/1 and PTU-treated mice (data not shown).
DISCUSSION
The sarcomeric cMyBP-C protein is essential for normal
cardiac function (7) and its phosphorylation by cAMP-
dependent protein kinase (PKA) is an important mechanism
that contributes to increased cardiac contractility in response
to b-adrenergic stimulation (41–44). Although there is
compelling evidence that cMyBP-C influences the activation
process of the cardiac sarcomere (12–14,19,45,46), the role
FIGURE 3 Biochemical analyses. (A) Typical electro-
phoresis of myosin solution stained with Coomassie Blue
and corresponding immunoblot with the anti-cMyBP-C
antibody. cMyBP-C was present in the myosin solution
from cMyBP-C1/1 (1/1) but not in cMyBP-C/ (/). (B)
phosphorylation levels of cMyBP-C before (base) and after
PKA treatment (PKA) of cMyBP-C1/1 myosin solution.
Values are means 6 SE, N ¼ 5/group; §p , 0.001.
FIGURE 4 Myosin mechanical function. (A–C) Distri-
bution of velocities of actin filament sliding over cardiac
myosins in cMyBP-C1/1 (1/1) (A), cMyBP-C/ (/) (B)
and after PKA treatment in cMyBP-C1/1 (P-cMyBP-C1/1)
(C). Velocities were shifted toward slower values in
cMyBP-C/ compared with cMyBP-C1/1 mice. Individ-
ual frame-to-frame velocities from tracked filaments are
plotted in a frequency histogram; n ¼ 200 filaments/group
(N ¼ 6/group). (D) Effects of immobilized a-actinin on
fraction of motile actin filaments in cMyBP-C1/1 (open
circles), cMyBP-C/ (solid circles), and after PKA treat-
ment in cMyBP-C1/1 (crossed circles). The lines are least-
squares regression fits:1/1: y¼0.5 x1 44.6, r¼ 0.73; /:
y ¼ 2.8 x 1 80.0, r ¼ 0.87; 1/11 PKA: y ¼ 0.8 x 1
91.7, r ¼ 0.93; and n ¼ at least 100 filaments/a-actinin
concentration from three-to-four separate experiments.
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of cMyBP-C in contractility and CB cycling remains difficult
to discern partly because other myofibrillar proteins, in-
cluding troponin I, are also targets of PKA-induced phos-
phorylation. Using a cMyBP-C/ mouse, we investigated
the contribution of cMyBP-C to actin-myosin interactions.
The CB model based on A. F. Huxley’s original CB model
and direct measurements of CB interactions in the in vitro
motility assays were analyzed.
In cMyBP-C/, we found that the probability of myosin
being weakly bound to actin was increased, in agreement
with earlier predictions that ablation of cMyBP-C increased
the likelihood of CB binding (14,19,45). On the basis of a
structural model, this has been attributed to the fact that ab-
lation of cMyBP-C reduces the distance between the myosin
head and actin binding sites (13), presumably as a result of
disrupted binding of cMyBP-C to the S2 domain of myosin
(9). Together, these results and data presented herein support
the view that the normal role of cMyBP-C is to limit myosin
binding to the thin filaments (14,15,47). As a consequence,
the increased number of weakly bound CB in cMyBP-C/
would contribute to the reduced relaxation rate reported both
in this study and in previous studies (21,22) given that re-
laxation rates are limited at least in part by the instantaneous
number of bound CBs (22,48). In contrast, during the force
generation step, the fraction of CBs in a strongly attached,
high force-generated state was severely reduced in cMyBP-
C/ (Figs. 1 and 2). This result is consistent with the
reduced CB-dependent stiffness previously reported in myo-
cardium from mice lacking cMyBP-C (49). Given that
muscle performance depends on both the number of CBs
generating force and the unitary force generated during the
power stroke (27), a reduced number of force-generating CBs
was a likely explanation for the depressed cardiac perfor-
mance in cMyBP-C/ mouse models (20,21). In addition,
the increased probability of weakly bound CBs associated
with the reduced probability of strongly bound, high-force
generated state CB (Fig. 2) indicated that the absence of
cMyBP-C impeded the transition from a weak to a strong CB
binding to actin. This may explain why that the slow phase
of force development, likely representing cooperative CB
recruitment, is absent in cMyBP-C/ myocardium (15).
Interestingly, the weak-to-strong binding transition step is
associated with conformational changes in myosin CBs (3)
that mainly involve swinging of the upper 50 K domain of the
myosin head (50,51). As a consequence, the myosin cardio-
myopathy loop, containing the first reported FHC missense
mutation, comes into contact with the actin surface (50), al-
lowing the actin-myosin CB to stroke. Our data thus raise the
possibility that altered CB binding is a common defect that
may contribute to the pathophysiology of FHC.
To investigate the force produced during the power-stroke
state, we used two independent methods, namely the CB
model based on Huxley’s equations (24,27) and the in vitro
motility assay in the presence of a-actinin, which opposes the
motion produced by the swing of the myosin head, thus
providing an index of myosin CB force (37,38). The in vitro
ability of skeletal heavy meromyosin to support movement of
actin filaments has been reported to be modulated by the
addition of recombinant N-terminal domains of cMyBP-C,
independently of myosin organization into thick filaments
(52). Our study extends the prior study by analyzing the ef-
fects of native cMyBP-C on cardiac myosin, at baseline, after
PKA-induced cMyBP-C phosphorylation and in the presence
of a-actinin. Our results indicate that the ability of cardiac
myosin to produce force during the power-stroke was
markedly reduced in cMyBP-C/ mice (Figs. 1 B and 4 D).
Therefore, cMyBP-C exerts a controlling influence over CB
power-stroke despite the low molar ratio of cMyBP-C to
myosin. This was associated with an acceleration of the
power-stroke rate, as attested by increased velocity of myosin
tilting during the stroke (Fig. 1 D). In addition, the total
duration of the CB cycle was nearly 40% shorter in cMyBP-
C/ (p, 0.05, Fig. 2 A), a result in agreement with previous
data suggesting that lack of cMyBP-C leads to an accelerated
CB cycle (15,17,53). Assuming that one ATP is hydrolyzed
per CB cycle (27,50), the normal function of cMyBP-C
would be to limit ATP consumption per CB force production
cycle. Taken together, these findings strongly suggest that
cMyBP-C enhanced the working stroke of myosin and reg-
ulated the tuning between the energy release from ATP hy-
drolysis and the force produced by the tilting of the myosin
head during the stroke.
The cMyBP-C phosphorylation level is a potential im-
portant regulator of cardiac function. In the absence of
cMyBP-C, the ability of the myocardium to respond to
b-adrenergic stimulation and the inotropic reserve are signifi-
cantly diminished (44). Furthermore, a recent study shows
that reduced cMyBP-C phosphorylation levels contribute at
least in part to the contractile dysfunction of the failing
FIGURE 5 Myosin isoformcomposition. (A)Representative electrophoretic
separation of LV myosin isoform composition in cMyBP-C1/1 (lanes 1–2),
cMyBP-C/ (lanes 3–4), and PTU-treated cMyBP-C1/1 mice (1/11PTU)
(lanes 5–6). (B) Quantitative a- and b-MHC are expressed as means 6 SE.
N ¼ at least 5/group, §p, 0.01 versus cMyBP-C1/1.
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human heart (36). The precise effects of cMyBP-C phos-
phorylation levels on contractility and CB cycling have,
however, remained difficult to determine because cardiac
troponin I and phospholamban are also targets of PKA-
induced phosphorylation (9,41). In this study, in vitro as-
says were performed with unregulated actin filaments, so
that the effects of PKA-mediated cMyBP-C phosphoryla-
tion could be investigated without the confusing effects on
other myofibrillar proteins. We found that the dominant
effect of cMyBP-C phosphorylation was to increase the
force produced bymyosin during the power-stroke (Fig. 4D).
Enhanced CB force can be explained by a more favor-
able position for CB attachment to actin (50,54), which
would occur as a consequence of cMyBP-C phosphoryla-
tion (9,39). Thus, although both ablation of cMyBP-C and
its phosphorylation critically regulate the distance between
the myosin heads and the actin binding sites, only phos-
phorylation of cMyBP-C would improve the orientation of
the myosin head in relation to actin. Taken as a whole, our
data provide new insights into the molecular mechanism
by which PKA-mediated phosphorylation of cMyBP-C
controls myocardium-enhanced cardiac function in re-
sponse to b-adrenergic stimulation.
Furthermore, we found that both unloaded muscle short-
ening and myosin sliding velocities were reduced in cMyBP-
C/. These changes could not be attributed to the moderate
increased in the slow, b-myosin isoform composition, given
that PTU-induced similar shift in the myosin isoform pattern
did not modify these parameters (Fig. 5). Alternatively, ab-
lation of cMyBP-C may conceivably reduce sliding velocity
due to a slower transition rate from the weakly to the strongly
attached actomyosin state (55,56).
Mechanical parameters were obtained from LV papillary
muscles. This raises questions as to whether some of the
observed data reflected the more general ventricular muscle.
However, no significant difference between papillary muscle
and whole LV was observed in regard to MHC composition.
Moreover, results obtained from in motility assays, i.e., at
constant number of myosin molecules per surface area,
clearly support papillary muscle experiments. Therefore,
impaired CB properties could not be attributed to potential
heterogeneity in the distribution of myosin isoforms or in
cardiac fibrosis.
Mouse models in which cMyBP-C has been knocked out
by homologous recombination, leading to deletion of the
entire coding sequence (16) or the transcription initiation site
(21), provide powerful tools to enable us to better understand
the role of cMyBP-C in myocardial contraction. However,
consistent with the absence of cMyBP-C, physiological
studies demonstrated contractile deficits and hypertrophy of
the hearts in the mutant mice (16,20,21,53,57). Therefore, it
is possible that some of the observed data in our cMyBP-C-
null mouse model are related to hypertrophic remodeling
rather than to cMyBP-C ablation. In addition, because
cMyBP-C is expressed at gestation day 8 in mice (58), car-
diac remodeling may begin at an early stage in mammalian
cardiac development. However, the phenotype of the present
homozygous mice is identical to what was observed in a
similar deficient cMyBP-C mouse model (16) and in homo-
zygous cMyBP-Ct/t (59). Moreover, cMyBP-C-null mice are
well-established, widely-used models to analyze the struc-
tural and functional consequences of cMyBP-C ablation
(15,16,18,20,21,53,57). It is notable that our study was per-
formed with native cMyBP-C. Therefore, interactions of
N-terminal domain of the cMyBP-C with either or both actin
and myosin could potentially influence discrete steps in the
CB cycle. Further studies are needed to precise the molecular
mechanisms by which the different regions of cMyBP-C
affects CB interactions.
In conclusion, we find that cMyBP-C slows the overall CB
cycle duration, confirming early studies (15,17,20,57). Our
data provide new insights into the specific steps at which
cMyBP-C regulates actin-myosin cycle and how potential
modifications of the myosin CB cycle contribute to the
cardiac dysfunction. Importantly, we find that cMyBP-C
prevents inefficient weakly bound CBs, enhances transition
from weakly bound to strongly bound CBs and increases
force produced during the power stroke. Moreover, CB force
production can be majored by PKA-based phosphorylation
of cMyBP-C. Thus, cMyBP-C is likely to play a significant
role in regulating the fine molecular tuning of the myosin CB.
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